All In Biotech

Drug Trial Radar · NCT06005441

A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

A Phase 2b, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection Compared With CBL-A1 and CBL-A2 for Reducing Abdominal Subcutaneous Fat

Last checked: Nov 19, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 173 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

173

Actual

Start

Nov 10, 2023

Primary completion

Oct 18, 2024

Study completion Oct 18, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared with CBL-A1 and CBL-A2 for reducing subcutaneous fat.

Conditions

  • Subcutaneous Fat

Interventions

  • CBL-514 injectionDrug

    Provided as a ready for use injectable CBL-514 solution

  • CBL-A1 InjectionDrug

    Provided as a ready for use injectable CBL-A1 solution

  • CBL-A2 InjectionDrug

    Provided as a ready for use injectable CBL-A2 solution

  • 0.9% Sodium ChlorideDrug

    Sodium Chloride (0.9% NaCl) placebo for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with at least 20% subcutaneous fat change compared to Baseline, of CBL-514 compared with placeboTime frame: From Baseline to 4 weeks after the final treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site 1

    Omaha, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.